T2 Biosystems, Inc. (TTOO) research, news, and more from GeoInvesting

Company description

Thu, 17 May 2018 14:42:34 GMT

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Research

Thu, 31 May 2018 14:53:28 GMT

T2 Biosystems (NASDAQ:TTOO)($7.74; $319.4M market cap) is a company that is working on developing a new test for diagnosing sepsis, one of the most prevalent and time sensitive complications that people can develop. On May 29, 2018 we stated we closed out our swing trade which we initiated on May 17, 2018 coupled with our reasons for tracking note.

This morning, the company announced the pricing of the 6.5 million share offering at a price of $7.50 per share. The offering explains why the stock did not hold pre-market highs on the day of its FDA marketing approval news on Tuesday. With the offering out of the way, we would not be surprised if the stock started to move higher once again.

Research

Tue, 29 May 2018 14:45:14 GMT

Closing Out Swing Trade In TTOO On FDA Approval

T2 Biosystems (NASDAQ:TTOO)($8.87, market cap $319.4m) - On May 17, 2018 we published our Reasons for Tracking on TTOO, a company that is working on developing a new test for diagnosing sepsis. We stated that “Getting this RFT note out as quickly as possible was our first goal as we believe an FDA decision on the company’s T2Bacteria could be imminent.” We had a speculative swing trade long position in the company that we disclosed at the same time. Special thanks to Geo Contributor Mr. Bio, who submitted the idea to us and helped us with our initial due diligence.

This morning, the company announced that it received market clearance from the U.S. Food and Drug Administration (FDA) for the T2Bacteria® Panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections. Management stated:

“The T2Bacteria Panel’s rapid results and high sensitivity make it a valuable tool for the diagnosis and management of suspected bloodstream infections,” said W. Frank Peacock, MD, FACEP, FACC, professor, associate chair, Baylor College of Medicine. “This is an important breakthrough as bacterial infections are a major cause of poor patient outcomes and high hospital costs. This is a game-changer.”

The stock traded higher in the pre-market trading session. At current pre market levels shares are up between 20% to 25% since the swing trade initiation.

Reasons For Tracking

Thu, 17 May 2018 15:33:34 GMT

Today, we are presenting a short “Reasons for Tracking” on T2 Biosystems, Inc. (NASDAQ:TTOO), a company that is working on developing a new test for diagnosing sepsis, one of the most prevalent and time sensitive complications that people can develop. The idea comes to us with help from a GeoInvesting member who works in the biotech industry.

Please see the RFT here.